Jürgen C. Dinger

Learn More
BACKGROUND The capacity of the AMS scale as clinical utility and as outcome measure still needs validation. METHODS An open post-marketing study was performed by office-based physicians in Germany in 2004. We analysed data of 1670 androgen-deficient males who were treated with testosterone gel. The AMS scale was applied prior to and after 3 months(More)
BACKGROUND Previous epidemiological studies have inconsistently shown a modestly increased breast cancer risk associated with hormone replacement therapy (HRT). Limited information is available about different formulations--particularly concerning different progestins. METHODS A case-control study was performed within Germany in collaboration with(More)
BACKGROUND A 24-day regimen of contraceptive doses of drospirenone and ethinylestradiol (DRSP/EE 24d) was recently launched. This regimen has properties which may be beneficial for certain user populations (e.g., women suffering from premenstrual dysphoric disorder or acne). However, it is unknown whether this extended regimen has an impact on the(More)
Little has been published about the impact of different HT formulations or ways of administration on gyneco-logical cancer risk. Two population-based case-control studies in collaboration with regional cancer registries and tumor centers in Germany were performed. Some 777 cases of ovarian cancer (OvC) and 1026 cases of uterine corpus cancer (UC) were(More)
BACKGROUND Most studies have found no increased risk of colon cancer associated with hormone replacement therapy (HRT), or even a decreased risk. But information about the effects of different HRT preparations is lacking. METHODS A case-control study was performed within Germany in collaboration with regional cancer registries and tumor centers. Up to 5(More)
BACKGROUND The post marketing safety surveillance program for a drug containing a new chemical entity should assess both, the safety outcomes that relate specifically to the targeted population, as well as those that could potentially be related to special pharmacological characteristics of the drug. Active safety surveillance using valid epidemiological(More)
BACKGROUND The Menopause Rating Scale is a health-related Quality of Life scale developed in the early 1990s and step-by-step validated since then. Recently the MRS scale was validated as outcomes measure for hormone therapy. The suspicion however was expressed that the data were too optimistic due to methodological problems of the study. A new study became(More)
  • 1